Helen Patterson

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.3K citations · Full text

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

David P. Dearnaley, Isabel Syndikus, G. Sumo et al. · The Lancet Oncology · 2011 · 304 citations · Full text

Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.

Michael R. Stratton, Stuart Moss, William Warren et al. · PubMed · 1990 · 179 citations

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Anna Wilkins, Helen Mossop, Isabel Syndikus et al. · The Lancet Oncology · 2015 · 149 citations · Full text